Review
Immunology
Shi-yue Zheng, Xin Du, Jian-zeng Dong
Summary: Sarcoidosis is a systemic inflammatory disease with varying clinical manifestations and diagnosis based on affected organs and pathological characteristics. Serum ACE level is commonly used as a biomarker in diagnosing sarcoidosis and analyzing its therapeutic effect and prognosis.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Gastroenterology & Hepatology
Zobair M. Younossi, Sean Felix, Thomas Jeffers, Elena Younossi, Brian Lam, Fatema Nader, Henry A. Tran, Ingrid Schneider, Maria Stepanova
Summary: Cardiovascular disease is common in patients with nonalcoholic fatty liver disease (NAFLD), and high-sensitivity cardiac troponin I (hs-cTnI) is associated with increased risk of coronary artery disease (CAD) in these patients.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Hong-Lei Ma, Sui-Dan Chen, Kenneth Zheng, Yue Yu, Xin-Xin Wang, Liang-Jie Tang, Gang Li, Rafael S. Rios, Ou-Yang Huang, Xiao-Yong Zheng, Ren-Ai Xu, Giovanni Targher, Christopher D. Byrne, Xiao-Dong Wang, Yong-Ping Chen, Ming-Hua Zheng
Summary: The TA allele of rs2070673 is strongly associated with lobular inflammation and NASH in NAFLD patients, with serum IP-10 levels playing a significant mediating role in this association.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Article
Cell Biology
Pengxiang Qu, Oren Rom, Ke Li, Linying Jia, Xiaojing Gao, Zhipeng Liu, Shusi Ding, Mingming Zhao, Huiqing Wang, Shuangshuang Chen, Xuelian Xiong, Ying Zhao, Chao Xue, Yang Zhao, Chengshuang Chu, Bo Wen, Alexandra C. Finney, Zuowen Zheng, Wenbin Cao, Jinpeng Zhao, Liang Bai, Sihai Zhao, Duxin Sun, Rong Zeng, Jiandie Lin, Wanqing Liu, Lemin Zheng, Jifeng Zhang, Enqi Liu, Y. Eugene Chen
Summary: The prevalence of NASH is increasing, highlighting the need to identify new targetable pathways for treatment. DT-109 has shown potential in attenuating steatohepatitis and fibrosis in mice, and a nonhuman primate model mimicking human NASH has been developed to enhance translatability. Using a multiomics approach, it was found that DT-109 reverses hepatic steatosis and prevents fibrosis progression, suggesting the need for clinical evaluation of DT-109.
Article
Biochemistry & Molecular Biology
Yvonne N. Flores, Aryana T. Amoon, Baolong Su, Rafael Velazquez-Cruz, Paula Ramirez-Palacios, Jorge Salmeron, Berenice Rivera-Paredez, Janet S. Sinsheimer, Aldons J. Lusis, Adriana Huertas-Vazquez, Sammy Saab, Beth A. Glenn, Folasade P. May, Kevin J. Williams, Roshan Bastani, Steven J. Bensinger
Summary: This study found differences in serum lipid composition between NAFLD patients and healthy controls, suggesting that specific lipid panels may be useful for predicting NAFLD diagnosis. Adjusting for various factors, a combination of ten lipids showed better predictive value for case or control status than an ROC curve area of 0.83.
LIPIDS IN HEALTH AND DISEASE
(2021)
Article
Gastroenterology & Hepatology
Oscar Gomez-Torres, Shripa Amatya, Lilly Kamberov, Hemangini A. Dhaibar, Pranshu Khanna, Oren Rom, Arif Yurdagul, A. Wayne Orr, Kelly Nunez, Paul Thevenot, Ari Cohen, Hrishikesh Samant, Jonathan S. Alexander, Emma Burgos-Ramos, Adrian Chapa-Rodriguez, Diana Cruz-Topete
Summary: The study identified SLAMF1 as a mediator of hepatocyte death in nonalcoholic fatty liver disease (NASH) and as a potential marker of NASH in humans. SLAMF1 levels were found to be significantly increased in the liver and plasma samples of NASH patients, suggesting a potential role as a noninvasive biomarker for the disease. Additionally, in vitro data indicate that SLAMF1 may serve as a therapeutic target to prevent hepatocyte death in NASH.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
(2022)
Article
Nutrition & Dietetics
Danijela Ristic-Medic, Marijana Kovacic, Marija Takic, Aleksandra Arsic, Snjezana Petrovic, Marija Paunovic, Maja Jovicic, Vesna Vucic
Summary: This study evaluated the effects of calorie-restricted Mediterranean and low-fat diets on patients with NAFLD. Both diets resulted in significant weight loss and improvements in liver status and cardiometabolic markers. The Mediterranean diet may have additional benefits compared to the low-fat diet by improving fatty acid profiles and FLI in NAFLD patients.
Article
Biochemical Research Methods
Adriana Zardini Buzatto, Jaspaul Tatlay, Barinder Bajwa, Dorothea Mung, Richard Camicioli, Roger A. Dixon, Liang Li
Summary: This study focused on discovering biomarkers for Parkinson's disease (PD) and predicting the transition to dementia using untargeted lipidomics. The proposed biomarker panels showed excellent performance in differentiating PD patients from healthy controls and identifying PD patients at risk of developing dementia. Further research with a larger sample size is needed to validate these findings.
JOURNAL OF PROTEOME RESEARCH
(2021)
Article
Endocrinology & Metabolism
Sami Qadri, Noora Ahlholm, Ida Lonsmann, Paola Pellegrini, Anni Poikola, Panu K. Luukkonen, Kimmo Porthan, Anne Juuti, Henna Sammalkorpi, Anne K. Penttila, Roberta D'Ambrosio, Giorgio Soardo, Diana J. Leeming, Morten Karsdal, Johanna Arola, Stergios Kechagias, Serena Pelusi, Mattias Ekstedt, Luca Valenti, Hannes Hagstrom, Hannele Yki-Jarvinen
Summary: This study investigated the impact of obesity on the performance of liver fibrosis biomarkers in NAFLD and found that ADAPT and FIB-4 are the best-performing biomarkers in obese patients, unaffected by body mass index.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Article
Endocrinology & Metabolism
Fangli Zhou, Yan Wang, Yujue Li, Mengjia Tang, Shan Wan, Haoming Tian, Xiang Chen
Summary: The study found that circulating sclerostin levels were significantly lower in NAFLD patients compared to controls, and were negatively correlated with multiple metabolic parameters in NAFLD patients. Mice fed on a high-fat diet had reduced bone mass and lower sclerostin expression levels. Therefore, liver-lipid-bone interactions may play a key role in abnormal bone metabolism in NAFLD.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Nutrition & Dietetics
Natalia Kopiczko, Anna Bobrus-Chociej, Ewa Harasim-Symbor, Eugeniusz Tarasow, Malgorzata Wojtkowska, Adrian Chabowski, Dariusz M. Lebensztejn
Summary: This study aimed to evaluate the serum FA concentration in children with obesity and NAFLD. The results showed that the total FA concentration was significantly higher in obese children and in obese children with NAFLD compared to controls. There was a significant positive correlation between total FA concentration and cholesterol, triacylglycerols, and insulin in children with NAFLD.
Article
Endocrinology & Metabolism
Qian Zhang, Xiaoqian Ma, Jie Xing, Haiyun Shi, Runkuan Yang, Yue Jiao, Shuohua Chen, Shouling Wu, Shutian Zhang, Xiujing Sun
Summary: This study investigated the association between obesity, serum uric acid, and incident NAFLD, finding that serum uric acid and obesity mediate the development of NAFLD, which is clinically significant.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Gastroenterology & Hepatology
Gang Li, Liang-Jie Tang, Pei-Wu Zhu, Ou-Yang Huang, Rafael S. Rios, Kenneth I. Zheng, Sui-Dan Chen, Hong-Lei Ma, Giovanni Targher, Christopher D. Byrne, Xiao-Yan Pan, Ming-Hua Zheng
Summary: The relationship between visceral fat accumulation and liver disease severity is influenced by PNPLA3 rs738409 gene polymorphism, particularly the G allele, which increases the risk of liver fibrosis in patients with biopsy-proven NAFLD.
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY
(2022)
Article
Medicine, General & Internal
Jeong-Ju Yoo, Eun Ju Cho, Goh Eun Chung, Young Chang, Yuri Cho, Sang-Hyun Park, Su-Min Jeong, Bo-Yeon Kim, Dong Wook Shin, Yun Joon Kim, Jung-Hwan Yoon, Kyungdo Han, Su Jong Yu
Summary: This study investigated whether nonalcoholic fatty liver disease (NAFLD) could be a precursor for metabolic syndrome (MetS) in young adults. The results showed that both the NAFLD group and the borderline NAFLD group had a higher risk of developing MetS compared to the control group. Additionally, all metabolic components were positively associated with the fatty liver index (FLI).
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Nutrition & Dietetics
Jonathan G. Stine, Jaclyn E. Welles, Shelley Keating, Zeba Hussaini, Christopher Soriano, J. Wes Heinle, Nathaniel Geyer, Vernon M. Chinchilli, Rohit Loomba, Scot R. Kimball
Summary: Exercise can reduce liver fat and improve biomarkers of liver fibrosis in NAFLD by decreasing serum fibroblast growth factor (FGF) 21 levels. This study suggests that the decrease in FGF21 may be a mechanism for the benefits of exercise in improving liver fat and fibrosis.